Log in

Relevant bibliographies by topics / Cardiovascular diseases

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Cardiovascular diseases'

Author: Grafiati

Published: 4 June 2021

Last updated: 30 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cardiovascular diseases.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cardiovascular diseases"

1

Subramanian, Geetha, Balaji Lohiya, and Dharmendra Jain. "Sex Hormones and Cardiovascular Diseases." Journal of Cardiovascular Medicine and Surgery 3, no. 2 (2017): 198–201. http://dx.doi.org/10.21088/jcms.2454.7123.3217.19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Basit Ashraf, Muhammad Abdul, Razia Rizwan, Mahwish Arooj, Arif Malik, and Sarmad Bashir. "CARDIOVASCULAR DISEASES." Professional Medical Journal 23, no. 11 (November 10, 2016): 1400–1411. http://dx.doi.org/10.29309/tpmj/2016.23.11.1770.

Full text

Abstract:

Background: Atherosclerosis, with chief contribution of vascular injury,inflammation and oxidative stress is the major cause of majority of cardiovascular diseases.Understanding of its pathophysiology provides initial prognosis, designing of new therapeuticsfor its prevention and different treatment protocols. Objectives: The present study wasdesigned to evaluate the role of oxidative and inflammatory markers of medical importancein the development of cardiovascular diseases. Study Design: Prospective case controlstudy. Setting: Sample collection from Punjab Institute of Cardiology (PIC), Lahore and allthe experimental work was done at Institute of Molecular Biology and Biotechnology (IMBB),The University of Lahore. Period: February 2015 to April 2016. Methodology: Biophysical,hematological, antioxidative capacity, inflammatory markers and lipid profile were estimatedin atherosclerotic patients. Results: The BMI (31.26±1.66) were significantly increased inatherosclerotic patients when were compared with controls. MDA was recorded as 3.99±0.16in atherosclerotic patients followed by 1.66±0.11 nmol/ml in healthy control respectively. Nitricoxide (NO) in the patients (35.26±4.26 ng/ml) was also significantly raised in the patientsthan normal subjects (21.26±2.35 ng/ml). Whereas mean serum levels of MPO and AGEsin patients were 0.237±.0013 pmol/ml and 2.46±0.09 U/ml respectively. Increased levels ofTCh (217.56±10.99, TG (199.67±11.02), and LDL (131.87±9.56) along with decrease in HDL33.76±3.85 mg/dl were recorded respectively. The hs-CRP showed significant increased levelsin atherosclerotic group (3.93±0.14mg/dl) as compared to normal control (1.68±0.06mg/L).The mean serum level of TNF-α and IL-6 in diseased group was recorded as 41.25±3.65pg/mland 6.35±0.64 pg/ml respectively. The significant decreasing trend of total anti-oxidant capacity,SOD, CAT, GSH, GPx, GRx, vitamin A and C but increasing drift of vitamin E was observed inatherosclerotic patients. Conclusion: Following study reported that elevated oxidative stressand inflammation along with lipid peroxidation are the major contributors in the progression ofatherosclerosis.

APA, Harvard, Vancouver, ISO, and other styles

3

Bognolo, G. "Cardiovascular diseases." BMJ 327, no. 7427 (December 6, 2003): 1354—a—1354. http://dx.doi.org/10.1136/bmj.327.7427.1354-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Archer, L. Nicholas J. "Cardiovascular diseases." Current Opinion in Pediatrics 2, no. 1 (February 1990): 91–94. http://dx.doi.org/10.1097/00008480-199002000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

FLACK, J. "Cardiovascular diseases." American Journal of Hypertension 10, no. 4 (April 1997): 227A. http://dx.doi.org/10.1016/s0895-7061(97)89485-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kakkar, Rahul, and Richard T. Lee. "Cardiovascular diseases." Drug Discovery Today: Disease Models 4, no. 4 (December 2007): 163–64. http://dx.doi.org/10.1016/j.ddmod.2008.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Macphee, Colin H., and Alan Daugherty. "Cardiovascular diseases." Drug Discovery Today: Therapeutic Strategies 5, no. 1 (March 2008): 1–3. http://dx.doi.org/10.1016/j.ddstr.2008.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Alpert, Joseph S. "Cardiovascular Diseases." JAMA: The Journal of the American Medical Association 254, no. 16 (October 25, 1985): 2264. http://dx.doi.org/10.1001/jama.1985.03360160096020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Viera, Anthony J. "Cardiovascular Diseases." Primary Care: Clinics in Office Practice 51, no. 1 (March 2024): i. http://dx.doi.org/10.1016/s0095-4543(23)00109-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Aslam, Dr Imran, Yuldashev Soatboy Jiyanboyevich, and Abdurakhmanova Zamira Ergashboevna. "Prevention & Treatment Of Cardiovascular Diseases." American Journal of Medical Sciences and Pharmaceutical Research 03, no. 06 (June 10, 2021): 180–88. http://dx.doi.org/10.37547/tajmspr/volume03issue06-28.

Full text

Abstract:

Cardiovascular disease is a significant problem that humans have always faced, affecting thousands of people's lives and health and taking the lives of many people. Many medical institutions and researchers have regarded it as a significant problem in overcoming the cardiovascular disease.1 Much attention has been paid, so the prevention and treatment level in this area has also been rapidly improved. However, cardiovascular disease still cannot be prevented or treated fundamentally, and it is still a significant danger to human health. All people still hope for breakthrough results in cardiovascular disease.2 This article analyzes the prevention and treatment of cardiovascular diseases, and has obtained a series of practical and reliable conclusions.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Cardiovascular diseases"

1

Gadd, Malin. "Cardiovascular diseases in immigrants in Sweden /." Stockholm : Neurotec, Center for family and community medicine, Karolinska institutet, 2006. http://diss.kib.ki.se/2006/91-7140-627-1/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Grytsiuk, M. І. "Life and cardiovascular diseases." Thesis, БДМУ, 2020. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/18306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Agyemang, Edmund Adjei, Priscilla Okoh, and K. O. Bobkovych. "Cardiovascular Diseases in Ghana." Thesis, «Інновації в медицині»: Тези доповідей 85-ої науково-практичної конференції студентів і молодих вчених із міжнародною участю (м. Івано-Франківськ, 24-25 березня 2016 р.). – м. Івано-Франківськ, 2016, 2016. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/11247.

Full text

Abstract:

Furthermore about 10% of the adult populations are tobacco smokers and 5-7% - obesity. All these data positively show why the occurrence of cerebrovascular diseases in Ghana is a rampant and should be of concern to all stakeholders.
Кафедра пропедевтики внутрішніх хвороб

APA, Harvard, Vancouver, ISO, and other styles

4

Abdi, Faduma Najmo Abdulrahman, and K. O. Bobkovych. "Cardiovascular diseases in Somalia." Thesis, «Інновації в медицині»: Тези доповідей 85-ої науково-практичної конференції студентів і молодих вчених із міжнародною участю (м. Івано-Франківськ, 24-25 березня 2016 р.). – м. Івано-Франківськ, 2016, 2016. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/11248.

Full text

Abstract:

Although the incidence has declined there appeared some fears that the aging population is increasing number of cases. As with other cardiovascular disease heart failure occurs more commonly in eastern and northern Somalia than in the south and southwest Somalia. The number of sufferers is probably declining. In 2010 the special rights to compensation of heart failure medication about 43 000 Somalis were given.
Кафедра пропедевтики внутрішніх хвороб

APA, Harvard, Vancouver, ISO, and other styles

5

Yiu, Kai-hang, and 姚啟恆. "Cardiovascular manifestations in systemic inflammatory diseases." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48541011.

Full text

Abstract:

Systemic inflammatory diseases, including those of rheumatology and dermatology, are associated with increased cardiovascular events. Evidence demonstrates that the chronic systemic inflammation associated with these diseases plays a pivotal role in all stages of atherosclerotic plaque formation, from initiation of the fatty streak to plaque rupture and consequent acute coronary syndrome. Although a number of studies have evaluated the cardiovascular manifestations in systemic inflammatory disease, this thesis offers additional observations, including the vascular atherosclerotic pattern, the pathogenesis of premature atherosclerosis and the use of coronary calcification as a predictor of adverse cardiovascular outcome. The work is divided into four sections. Section I provides an overview of the cardiovascular manifestation of systemic inflammatory diseases and the patients and methods of the current thesis. The objective of Section II is to evaluate the pattern of cardiovascular manifestation, in particular systemic vascular calcification and cardiac valve calcification in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis, using multi-detector computed tomography (MDCT) and carotid intima-media thickness (c-IMT). It was found that both patients with RA, SLE and psoriasis had a greater prevalence and extent of vascular calcification compared with age and gender matched controls. Moreover, both aortic valve calcification (AVC), mitral valve calcification (MVC) was found to be more prevalent in patients with RA and SLE than controls. Interestingly, the presence of MVC, but not AVC, independently predicted the occurrence of premature atherosclerosis with arterial calcification in these patients. Section III evaluates the potential underlying mechanisms that lead to cardiovascular manifestations in patients with systemic inflammatory disease. Bone marrow-derived endothelial progenitor cells (EPCs) play an important role in the maintenance of endothelial integrity and hemostasis. The relationship between the circulating EPCs and subclinical coronary atherosclerosis as determined by coronary calcification in RA patients nonetheless remains unclear. The study results demonstrated that RA patients with coronary atherosclerosis have significantly lower levels of CD133/KDR+ and CD133+ EPCs than those without. In addition to older age, lower levels of circulating CD133/KDR+ EPCs also predicted occurrence of coronary atherosclerosis. As with RA and SLE, psoriasis is associated with premature atherosclerosis, although the underlying mechanism remains unclear. The aim of the study was therefore to investigate the relationship of disease activity and systemic inflammation with macrovascular and microvascular function in patients with psoriasis. The results demonstrated that patients with psoriasis have increased arterial stiffness, but not microvascular dysfunction compared with healthy controls. More importantly, high-sensitivity C reactive protein positively correlated with, and independently predicted, arterial stiffness. Section IV explores the prognostic value of a surrogate marker of atherosclerosis, coronary calcium score (CCS), in patients with RA and SLE. A total of 152 patients with RA (n=85) and SLE (n=69), and 106 healthy controls underwent MDCT to measure CCS. All patients were prospectively followed up for major cardiovascular events for a mean period of 4.3 years. The result demonstrated that presence of CCS >100 predicted the occurrence of a major cardiovascular event independent of other risk factors in RA and SLE patients.
published_or_final_version
Medicine
Master
Doctor of Medicine

APA, Harvard, Vancouver, ISO, and other styles

6

Li, Wai-sum Rachel, and 李蕙琛. "Effects of abacavir on cardiovascular system." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B46330288.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Qianyi. "Fatty Acids, Cardiovascular Diseases, and Diabetes Mellitus." Thesis, Harvard University, 2015. http://nrs.harvard.edu/urn-3:HUL.InstRepos:14117764.

Full text

Abstract:

Cardiovascular disease (CVD) is the number one cause for mortality and morbidity around the world. Meanwhile, diabetes mellitus (DM) has become an emerging epidemic, causing 1.5 million deaths in 2012, with 80% occurring in low- and middle-income countries. Substantial evidence has linked both lifestyle and metabolic risk factors to increased risk of CVD and death, with suboptimal diet being the single leading modifiable cause of poor health (Lim. SS, et al, Lancet 2012). Of 20 top individual causes of disease burden worldwide, 8 are related to poor nutrition, including suboptimal intakes of various dietary fatty acids. Although previous studies have found divergent health effects of different dietary fatty acids on health, gaps still exist in terms of the scientific knowledge (e.g. how individual circulating vs. dietary trans fatty acid subtypes affect health) and related disease burdens (e.g. national CHD mortality burdens attributable to suboptimal intakes of fatty acids). These gaps have motivated my dissertation researches. In chapter one and two, I investigated the prospective associations of five subtypes of plasma phospholipid trans fatty acid (TFA) levels with the risk of various disease endpoints, including total, CVD and non-CVD mortality, incident coronary heart disease (CHD) and DM. In chapter two, I also examined the prospective associations of total and subclasses dietary TFA with risk of DM. The analyses were conducted using the Cardiovascular Health Study, a community-based multicenter prospective cohort consisted of older Americans. The risks were estimated using the Cox proportional hazard model. The study in chapter three was a collaborative effort of the Nutrition and Chronic Diseases Expert Group as part of the 2010 Global Burden of Diseases, Injuries, and Risk Factors study. Using the comparative risk assessment framework, I comprehensively quantified the CHD mortality attributable to suboptimal intakes of saturated fat, omega-6 polyunsaturated fat, and TFA in 186 countries in 1990 and 2010, by age and sex groups. I also estimated the regional and country level trends of these attributable CHD burdens from 1990 to 2010. The findings of this study are relevant for informing regional and country level public health policy priorities.

APA, Harvard, Vancouver, ISO, and other styles

8

BIFFI, ANNALISA. "Antidepressants and the risk of cardiovascular diseases." Doctoral thesis, Università degli Studi di Milano-Bicocca, 2018. http://hdl.handle.net/10281/199081.

Full text

Abstract:

La sindrome depressiva è considerata una importante questione nel campo della sanità pubblica. Oggigiorno, circa 300 milioni di persone sono colpiti da disturbi depressivi e un quarto di questi solo in Europa. La terapia con antidepressivi AD come i farmaci triciclici TCA, inibitori selettivi della ricaptazione della serotonina SSRI e nuovi AD atipici, sembra essere il trattamento più appropriato per la cura dei sintomi depressivi. Diversi studi sono realizzati per valutare l’associazione tra trattamento con farmaci AD e insorgenza di patologie cardiovascolari CV. Nel primo studio, è stata eseguita una sintesi della letteratura scientifica riguardante la possibile associazione tra l’utilizzo di AD e patologie CV. È stata eseguita una ricerca di studi osservazionali utilizzando termini collegati alle patologie CV e al trattamento con AD. In più, è stata valutata la qualità degli studi inclusi, l’eterogeneità tra questi e la presenza di publication bias. La seconda parte della tesi riguarda studi condotti entro il progetto AIFA Agenzia Italiana del Farmaco, dove sono stati utilizzati dati da diversi database sanitari regionali partecipanti a I-GrADE Gruppo Italiano per l’Appropriata Prescrizione Farmacologica nei soggetti Anziani. Il progetto si focalizza sull’inappropriatezza delle prescrizioni in una popolazione anziana con diagnosi CV. Nel secondo studio, disegni caso-controllo innestati sono stati applicati per valutare la terapia AD rispetto all’insorgenza di patologie CV. Analisi di sensibilità sono state effettuate come una Monte Carlo Sensitivity Analysis, che ha valutato il potenziale bias introdotto dal confondente fumo e modificando l’ampiezza della finestra di esposizione. Nel terzo studio, l’effetto acuto del trattamento con AD è stato valutato rispetto all’insorgenza di aritmia. La selezione della coorte è stata ristretta ai nuovi utilizzatori di AD senza precedente aritmia. Disegni caso-controllo innestato e case-crossover sono stati applicati e le stime sono state aggiustate per le prescrizioni di farmaci e i ricoveri. Analisi di sensibilità sono state effettuate utilizzando diversi criteri per definire l’outcome e modificando la finestra di esposizione. Nel quarto studio, è stato valutato il link tra aderenza al trattamento con AD rispetto alla mortalità. La selezione è stata ristretta agli utilizzatori di AD trattati dal reclutamento in coorte. Un modello di Cox è stato applicato ed è stata valutata la combinazione tra diversi livelli di aderenza ad AD a co-trattamenti durante il periodo di osservazione. Le stime sono state aggiustate per diverse variabili, come la politerapia. Infine, analisi di sensibilità sono state effettuate applicando una diversa definizione per la copertura con AD. I risultati della meta-analisi hanno mostrato un incremento di rischio di patologie cerebrovascolari e di cardiopatie acute rispettivamente per utilizzatori di SSRI e TCA. Questi risultati sono confermati dagli studi osservazionali effettuati nell'ambito del Progetto AIFA. Una relazione positiva è stata trovata tra esposizione con AD e malattie CV, in particolare un effetto proaritmico dell'esposizione AD è stato rivelato in una coorte di pazienti anziani già affetti da una malattia CV. Infine, l'aderenza al trattamento AD è stata associata ad un ridotto rischio di morte, considerando diversi livelli di aderenza di co-trattamenti assunti durante il periodo di osservazione. In conclusione, gli studi condotti hanno mostrato che l’uso di AD sembra incrementare il rischio di patologie CV, perciò i medici devono attentamente monitorare il trattamento con AD per assicurarne la corretta assunzione e provare a prevenire l’insorgenza di patologie CV. Poiché il potenziale aumento del rischio può comportare un impatto considerevole, le stime fornite da questi studi possono supportare sia le pratiche cliniche che normative.
Depression is considered an important public health issue. Nowadays, about 300 million people are affected by depressive disorders and a quarter of them just in Europe. Antidepressant (AD) treatment like tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) or newer atypical antidepressants (NAAs) seems to be the most appropriate therapy in order to treat depressive symptoms. In the first study, a synthesis of the available scientific literature was performed on the possible association between use of AD and cardiovascular diseases (CVD). A search of published observational studies was carried out using terms directly related with cardiovascular and antidepressive field. In addition, the quality of the included studies, the heterogeneity among them as well as the presence of publication bias was evaluated. The second part of the thesis regards the studies conducted within the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) project, where data from different regional healthcare utilization databases involved in the Italian Group for Appropriate Drug Prescription in the Elderly (I-GrADE) was used. The project is focused on the evaluation of inappropriate prescribing in a population of elderly hospitalized with a diagnosis of CVD. In the second study, nested-case control studies were applied for the evaluation of the role of AD respect to the occurrence of CVD, among the elderly population. Sensitivity analyses were performed, like a Monte Carlo Sensitivity Analysis (MCSA), which quantified the potential bias introduced by a particular confounder (smoking factor) and by changing the length of AD exposure’s window. In the third study, the acute effect of AD treatment was evaluated respect to the onset of arrhythmia. The cohort selection was restricted to the new AD users who did not developed a previous event of arrhythmia. Nested case-control and case-crossover studies were applied and estimates were adjusted for drug prescriptions and hospitalizations. Sensitivity analyses were performed by using different criteria to define the outcome of interest or by changing length of AD exposure’s window. In the fourth study, we focused on the role of AD medication respect to mortality. The possible link between adherence to AD and increased or decreased risk of mortality was tested among the elderly cohort. The selection was restricted to elderly who were all AD users and started AD therapy since cohort recruitment. A Cox model was applied and the combined levels of adherence to AD and co-treatments were evaluated during observation time. Estimates were adjusted for several variables such as the polypharmacy. Then, sensitivity analyses were performed on the basis of AD coverage’s definition. The results of the meta-analysis showed a significant increased risk of cerebrovascular disease and acute heart failure respectively for SSRIs and TCA users. Then, these results were confirmed by the observational studies performed within the AIFA Project. A positive relation was found between AD exposure and CVD in a cohort of elderly patients already affected by a CVD, in particular a proarrhythmic effect of AD exposure was revealed by our estimates. Finally, adherence to AD treatment was associated with a decreased risk of death by considering different levels of adherence to co-treatments assumed during the observation time. In conclusion, these studies showed that the use of AD could increase the risk of several CV disease, therefore, physicians need to carefully monitor their patients to ensure a correct assumption of the drugs and concurrently try to prevent the onset of CV outcomes. Since any potential increased risk may result in a considerable impact, the risk effect estimates provided by these studies may support both clinical practices and regulatory activities.

APA, Harvard, Vancouver, ISO, and other styles

9

Rosenlund, Mats. "Environmental factors in cardiovascular disease /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-292-6/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Gobin, Reeta Rukmini Devi. "Metabolic syndrome and cardiovascular disease." Thesis, University of Cambridge, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Cardiovascular diseases"

1

Murad, Ferid, Atta-ur-Rahman, and Ka Bian, eds. Cardiovascular Diseases. UAE: Bentham Science Publishers Ltd., 2017. http://dx.doi.org/10.2174/97816810848931170101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Office, Great Britain Welsh, Gwent Health Authority, and Protocol Enhancement Project, eds. Cardiovascular diseases. [Cardiff]: [Welsh Office], 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Taylor, Robert B., Alan K. David, D. Melessa Phillips, Scott A. Fields, and Joseph E. Scherger, eds. Taylor’s Cardiovascular Diseases. New York: Springer-Verlag, 2005. http://dx.doi.org/10.1007/b138863.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Akinkugbe, O. O. Cardiovascular disease. Oxford: Blackwell Scientific, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Evans, Mary Jane R. Cardiovascular nursing. Springhouse, Pa: Springhouse Corp., 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Baune, Bernhard T., and Phillip J. Tully, eds. Cardiovascular Diseases and Depression. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-32480-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Eliseev, Oleg M. Cardiovascular Diseases and Pregnancy. Berlin, Heidelberg: Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73605-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lenzi, S., and G. C. Descovich, eds. Atherosclerosis and Cardiovascular Diseases. Dordrecht: Springer Netherlands, 1987. http://dx.doi.org/10.1007/978-94-009-3205-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Veronese, Nicola, ed. Frailty and Cardiovascular Diseases. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-33330-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Andrade, Jadelson, Fausto Pinto, and Donna Arnett, eds. Prevention of Cardiovascular Diseases. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22357-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Cardiovascular diseases"

1

Bidulescu, Aurelian, and Methode Bacanamwo. "Cardiovascular Diseases." In Nutrition in Epigenetics, 173–87. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9780470959824.ch10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ladd, Susanne, Harald Kramer, Christoph R. Becker, Norbert Weiss, and Ulrich Hoffmann. "Cardiovascular Diseases." In Screening and Preventive Diagnosis with Radiological Imaging, 149–82. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-49831-5_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tiwari, Jawahar L., and Paul I. Terasaki. "Cardiovascular Diseases." In HLA and Disease Associations, 352–62. New York, NY: Springer New York, 1985. http://dx.doi.org/10.1007/978-1-4613-8545-5_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Wolman, Benjamin B. "Cardiovascular Diseases." In Psychosomatic Disorders, 133–43. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-5520-5_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hoffman, Richard, and Mariette Gerber. "Cardiovascular Diseases." In The Mediterranean Diet, 258–92. West Sussex, UK: John Wiley & Sons, Ltd., 2013. http://dx.doi.org/10.1002/9781118785027.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Hupp, Wendy S. "Cardiovascular Diseases." In The ADA Practical Guide to Patients with Medical Conditions, 25–42. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781119121039.ch2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Menotti, Alessandro. "Cardiovascular Diseases." In The Mediterranean Diets in Health and Disease, 232–51. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-6497-9_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Verjans, Johan, Wouter B. Veldhuis, Gustavo Carneiro, Jelmer M. Wolterink, Ivana Išgum, and Tim Leiner. "Cardiovascular Diseases." In Artificial Intelligence in Medical Imaging, 167–85. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-94878-2_13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lancaster, H. O. "Cardiovascular Diseases." In Expectations of Life, 252–65. New York, NY: Springer New York, 1990. http://dx.doi.org/10.1007/978-1-4612-1003-0_25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Raczynski, James M., Martha M. Phillips, Carol E. Cornell, M. Janice Gilliland, Bonnie Sanderson, and Vera Bittner. "Cardiovascular Diseases." In Handbook of Health Promotion and Disease Prevention, 231–59. Boston, MA: Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-4789-1_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cardiovascular diseases"

1

Vinzey, Hrishikesh, Aditya Tidke, Prachi Palsodkar, Soham Kottawar, Yogita Dubey, and Punit Fulzele. "Predictive Analysis of Cardiovascular Diseases." In 2022 International Conference on Emerging Trends in Engineering and Medical Sciences (ICETEMS). IEEE, 2022. http://dx.doi.org/10.1109/icetems56252.2022.10093374.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wang, Jingying. "Lipoproteins and Atherosclerotic Cardiovascular Diseases." In International Conference on Health Big Data and Intelligent Healthcare. SCITEPRESS - Science and Technology Publications, 2022. http://dx.doi.org/10.5220/0011371300003438.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Карпин, Владимир Александрович, and Ольга Ивановна Шувалова. "INTESTINAL MICROBIOTA AND CARDIOVASCULAR DISEASES." In Высокие технологии и инновации в науке: сборник статей LII международной научной конференции (Санкт-Петербург, Май 2024). Crossref, 2024. http://dx.doi.org/10.37539/240527.2024.23.78.002.

Full text

Abstract:

Последние достижения в изучении клинической микробиологии открыли новую страницу в представлении о микробном сообществе и его взаимоотношениях с человеческим организмом, включая развитие различных патологических процессов. В данном сообщении обсуждается возможная связь различных дисбиозов кишечника с заболеваниями сердечно-сосудистой системы. Обсуждаются потенциальные лечебные стратегии, направленные на нормализацию микроэкологии у кардиологических больных. Recent advances in the study of clinical microbiology have opened a new page in the understanding of the microbial community and its relationship with the human body, including the development of various pathological processes. This report discusses the possible connection of various intestinal dysbioses with diseases of the cardiovascular system. Potential therapeutic strategies aimed at normalization of microecology in cardiac patients are discussed.

APA, Harvard, Vancouver, ISO, and other styles

4

Jo-Avila, Miguel, Ahmed Al-Jumaily, and Jun Lu. "Predictive Cardiovascular Model With Blood Flow Measurements." In ASME 2015 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2015. http://dx.doi.org/10.1115/imece2015-51993.

Full text

Abstract:

Cardiovascular disease is one of the leading causes of death in the world, accounting for 30% of all deaths worldwide and 40% of those occurring in New Zealand. In recent years, engineers and scientists have collaborated with the medical community to find new methodologies and approaches for assessing, investigating and understanding the development of cardiovascular diseases. Elements such as computational models developed with fluid dynamic elements (CFD/FE) have become excellent tools for this purpose. One of the important approaches is developing devices for investigating the central blood flow and pressure, and correlating the results to different heart diseases. Higher-valued changes in central blood flow and pressure mean that the heart must work harder. A computational model capable of predicting inlet and outlet locations of a blockage would be helpful to determine different stages of cardiovascular disease. By using reflection signals from the central blood flow that are detected at locations such as the brachial artery or subclavian artery, it is possible to model the effect of flow and pressure differences on heart diseases.

APA, Harvard, Vancouver, ISO, and other styles

5

Mesihović-Dinarević, Senka. "WHAT IS NEW IN CARDIOVASCULAR MEDICINE?" In Symposium with International Participation HEART AND … Akademija nauka i umjetnosti Bosne i Hercegovine, 2019. http://dx.doi.org/10.5644/pi2019.181.03.

Full text

Abstract:

The rapid pace of change continues to be a hallmark in cardiovascular medicine and many see that pace accelerating in adult cardiovascular medicine as well as in paediatric cardiology medicine. Cardiovascular medicine is an area of clinical practice with a continually rapid expansion of knowledge, guidelines, best practices and new technology. Cardiovascular diseases are the leading cause of mortality in the world and cause major costs for the health sector and economy. Primary care clinicians are challenged to optimally manage a multitude of diseases including congestive heart failure, coronary artery disease, valvular diseases, arrhythmias, lipid disorders, and hypertension. Multimodality imaging techniques are being used more frequently as their utility is better appreciated. Echocardiography has been the mainstay approach, cardiac computerized tomography and magnetic resonance imaging provide a good imaging alternative for patients with multiple complex surgeries. 3D printing has seen a rapid growth in use for planning treatments for patients with congenital heart disease. Simulation using 3D models is emerging as a fundamental resource for teaching procedural techniques and a new standard of care. Artificial intelligence holds the greatest potential for revolutionizing medicine. Innovative technologies in the world of cardiovascular health are expanding every day: wearable computing technologies, bioresorbable stents, leadless pacemaker, valve-in-valve procedure, protein patch for heart muscle growth and others. As a part of lifelong learning process for all professionals in cardiovascular medicine, the imperative is to have continuity of reviewing novelties, with results data from numerous researches in order to treat patient according to best practices and evidence-based medicine.

APA, Harvard, Vancouver, ISO, and other styles

6

Lebedeva, O. D. "Non-medicinal technologies for cardiovascular diseases." In Arbat readings. Знание-М, 2020. http://dx.doi.org/10.38006/907345-01-0.2020.66.71.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hennig, Andreas, Gerd vom Bogel, and Anton Grabmaier. "Sensor transponder system for cardiovascular diseases." In 2012 IEEE International Conference on RFID-Technologies and Applications (RFID-TA). IEEE, 2012. http://dx.doi.org/10.1109/rfid-ta.2012.6404567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

YAMAGUCHI, TAKAMI, HITOSHI KONDO, YUJI SHIMOGONYA, YOHSUKE IMAI, NORIAKI MATSUKI, and TAKUJI ISHIKAWA. "COMPUTATIONAL BIOMECHANICS FOR INVESTIGATING CARDIOVASCULAR DISEASES." In Proceedings of the Tohoku University Global Centre of Excellence Programme. PUBLISHED BY IMPERIAL COLLEGE PRESS AND DISTRIBUTED BY WORLD SCIENTIFIC PUBLISHING CO., 2009. http://dx.doi.org/10.1142/9781848163539_0004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Chocarro, Luisa, Ester Blanco, Hugo Arasanz, Leticia Fernández Rubio, Miriam Echaide, Maider Garnica, Pablo Ramos, Sergio Piñeiro, Grazyna Kochan, and David Escors. "LAG-3 Role in Cardiovascular Diseases." In MOL2NET'22, Conference on Molecular, Biomedical & Computational Sciences and Engineering, 8th ed. - MOL2NET: FROM MOLECULES TO NETWORKS. Basel, Switzerland: MDPI, 2022. http://dx.doi.org/10.3390/mol2net-08-12448.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bhupalam, Manideep, Hari Charan Reddy Manthoor, and Ananthakrishna Thalengala. "Classification of Cardiovascular Diseases using PCG." In 2023 International Conference on Modeling, Simulation & Intelligent Computing (MoSICom). IEEE, 2023. http://dx.doi.org/10.1109/mosicom59118.2023.10458727.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cardiovascular diseases"

1

Wang, Yuchen. How does Veteran Status Affect Risk of Cardiovascular Diseases? Ames (Iowa): Iowa State University, January 2019. http://dx.doi.org/10.31274/cc-20240624-843.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lampley, Katrice, and Nicole Therrien. "Geisinger Ambulatory Pharmacy Care Program Field Notes". National Center for Chronic Disease Prevention and Health Promotion (U.S.)., 2023. http://dx.doi.org/10.15620/cdc:126232.

Full text

Abstract:

These Field Notes summarize the Geisinger Ambulatory Care Program’s care coordination work with pharmacists alongside other health care team members to manage chronic diseases including cardiovascular disease.

APA, Harvard, Vancouver, ISO, and other styles

3

O’Connell, Joan, Jennifer Rockell, Margaret Reid, Kathleen Harty, Marcelo Perraillon, and Spero Manson. Improving Health Outcomes among Native Americans with Diabetes and Cardiovascular Diseases. Patient-Centered Outcomes Research Institute (PCORI), November 2020. http://dx.doi.org/10.25302/11.2020.ad.13046451.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Zhang, Mingzhu, Wujisiguleng Bao, Luying Sun, Zhi Yao, and Xiyao Li. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0020.

Full text

Abstract:

Review question / Objective: To assess the beneficial effect and safety of finerenone for patients with chronic kidney disease associated with type 2 diabetes. Condition being studied: Chronic kidney disease (CKD) is a major contributor to morbidity and mortality from non-communicable diseases, affecting almost 700 million people worldwide. Approximately 40% of patients with diabetes have CKD, which exposes them to a 3-fold higher risk of cardiovascular death versus those with T2D alone. Strategies to protect the kidneys of patients with CKD and T2D may reduce their risk of cardiovascular events. Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced composite kidney and cardiovascular outcome in trials involving patients with chronic kidney disease. Recently, quite a few clinical studies have been conducted to compare finerenone and placebo. Our meta-analysis aimed to investigate the efficacy and safety of finerenone in chronic kidney disease associated with T2D. 1st author* - Mingzhu Zhang and Wujisiguleng Bao contributed equally to this study.

APA, Harvard, Vancouver, ISO, and other styles

5

Jin, Soyeon, and Peter Kang. A Systemic Review on Advances in Management of Oxidative Stress-Associated Cardiovascular Diseases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2024. http://dx.doi.org/10.37766/inplasy2024.7.0064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, Yangjun, Wei Xie, Zbigniew Ossowski, Juan Li, Juan Yang, Yiming Luo, Xia Wu, and Liying Liu. Physical activity, abdominal obesity and inflammatory response in the elderly: a systematic review and meta-analysis of randomized-controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0051.

Full text

Abstract:

Review question / Objective: The purpose of this study was to explore the effects of physical activity (i.e., type of exercise, FITT criteria, control group, other interventions) on abdominal obesity and inflammatory response in elderly? The study method was a randomized controlled trial. Condition being studied: An increasing number of studies have demonstrated that chronic inflammation is closely associated with the initiation and progression of a broad range of age-related diseases, such as cardiovascular disease, cancer, diabetes, Alzheimer’s disease, and other neurodegenerative diseases and is an independent risk factor for mortality in healthy adults. Moreover, there is strong evidence that the development of age-related diseases is linked to low-grade elevation of circulating inflammatory mediators. Therefore, future interventional researches should focus on preserving overall homeostatic balance and controlling inflammatory status in the aging patient.

APA, Harvard, Vancouver, ISO, and other styles

7

Gupta, Shweta. Obesity: A Lifestyle Choice or a Disease? Nature Library, October 2020. http://dx.doi.org/10.47496/nl.blog.07.

Full text

Abstract:

Obesity isn’t an overnight phenomenon but slowly develops from poor lifestyle choices and an unhealthy diet, which increases the risk of other health problems such as cardiovascular diseases, high blood pressure, diabetes and even cancer.

APA, Harvard, Vancouver, ISO, and other styles

8

Cabrera-Aguilera, Ignacio, Gonzalo Latin-Rivera, Rodrigo Torres-Castro, Camen Gloria Zambrano, Isabel Blanco, Sonia Ruiz-Bustillo, Lluis Recasens, Nuria Farré Lopez, Elena Gimeno-Santos, and Jordi Vilaró. Effects of exercise on the expression of angiogenesis-precursor biomarkers in cardiovascular diseases: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Keshav, Dr Geetha, Dr Suwaibah Fatima Samer, Dr Salman Haroon, and Dr Mohammed Abrar Hassan. TO STUDY THE CORRELATION OF BMI WITH ABO BLOOD GROUP AND CARDIOVASCULAR RISK AMONG MEDICAL STUDENTS. World Wide Journals, February 2023. http://dx.doi.org/10.36106/ijar/2405523.

Full text

Abstract:

Introduction: Advancements and increase in access to healthcare have increased the life expectancy in India from 32 years in 1947 to almost 70 years currently. Due to robust vaccination and basic health programs, most of the communicable diseases are kept under control. The disease burden is now skewed towards non-communicable diseases. It is an established fact that body mass index (BMI) is a reliable predictor of cardiovascular disease (CVD) later in life. Early prediction can decrease the disease load and enable early preventative measures. A more novel approach of connecting it with blood groups would yield profound results in predictability and subsequent management. This study was done to see correlation between BMI and known blood groups in order to predict the potential incidence of CVDs in medical students. Material and Method - A cross-sectional descriptive study was conducted in Bhaskar Medical College from September 2022 - November 2022. The sample population included 150- 1st year medical students chosen by Randomized sampling method. BMI was calculated based as weight in kilograms divided by the square of the height in meters (kg/m2). Discussion - Many studies conducted on the association of Blood groups with BMI yielded mixed and inconclusive results. On analysis of the data obtained from this study, O- positive blood group showed the highest inclination towards obesity i.e. 30 of the total participants. A-positive and B- positive blood groups were shown to have a lesser association with obesity i.e. 11 participants of the 150. These results were in accordance with a study done among female students by Shireen Javad et.al, nding blood group O to be the most prone to obesity.8 Incompatible to our results, a study conducted by Samuel Smith Isaac Okai et.al. found no signicant association between blood groups and BMI.10 Another study conducted by Christina Ravillo et.al. found that blood group O had the highest and blood group AB with lowest prevalence of obesity9. These ndings were similar to the results obtained in our study. To study the correlation of BMI with ABO blood group and Cardiovascula AIMS and OBJECTIVES Aim: - r risk among medical students. 1. Calculate and segregate the participants according to BM Objectives: - I using the standard formula provided by the WHO. 1. Determine Blood group using antisera 2. Evaluation of Lipid prole in obese individuals

APA, Harvard, Vancouver, ISO, and other styles

10

FEDOTKINA, S. A., O. V. MUZALEVA, and E. V. KHUGAEVA. RETROSPECTIVE ANALYSIS OF THE USE OF TELEMEDICINE TECHNOLOGIES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF HYPERTENSION. Science and Innovation Center Publishing House, 2021. http://dx.doi.org/10.12731/978-0-615-67320-2-4-22.

Full text

Abstract:

Introduction. The economic losses associated with disability due to diseases of the circulatory system, as well as the costs of providing medical care to patients suffering from heart and vascular diseases, are increasing annually. The state preventive measures currently being carried out are of a delayed nature. The results of the medical examination of the population of the Russian Federation in recent years (2015-2019) indicate that the incidence of cardiovascular diseases, including hypertension, is at a fairly high level. In the middle of the last century, the Concept of risk factors for the development of chronic non-communicable diseases were formulated, in the structure of which cardiovascular diseases, including arterial hypertension, occupies one of the primary positions. The concept is based on the results of promising epidemiological studies, and, at present, is a methodological basis for planning and organizing primary prevention of cardiovascular diseases. The purpose of the study. Based on the analysis of literary sources (including foreign ones) containing experience in the use of telemedicine technologies, to assess their significance for the prevention, diagnosis and treatment of hypertension, as well as forecasting improvements in the quality of medical care when adapting to the use of clinical recommendations. Materials and methods. The article provides an analytical review of the use of modern telemedicine technologies in the prevention of hypertension. The results of the study and their discussion. The analysis of literary sources has shown that in the context of the progress of information and telecommunication technologies in the healthcare system, a fundamentally new direction has appeared in the organization and provision of medical care to the population - telemedicine, which will ensure the modern level of prevention, detection and treatment of chronic non-communicable diseases, and also determines positive medical, social and economic performance indicators. To date, updates in the legislative framework of the Russian Federation are aimed at ensuring that medical care with the use of telemedicine technologies is more widespread, taking into account the standards of medical care and clinical recommendations. Conclusion. Based on a review of literature sources, it has been established that the modern solution to the problem of improving the quality of medical care for patients, including those with hypertension, diseases is medical care using telemedicine technologies that prove their medical, social and economic effectiveness.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!